---
title: Evaluation of Clinical Outcomes and Costs of a Lifestyle Intervention in Obese Infertile Women
nct_id: NCT01483612
overall_status: COMPLETED
phase: NA
sponsor: Université de Sherbrooke
study_type: INTERVENTIONAL
primary_condition: Female Infertility
countries: Canada
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT01483612.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT01483612"
ct_last_update_post_date: 2023-02-02
last_seen_at: "2026-05-12T07:16:06.785Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Evaluation of Clinical Outcomes and Costs of a Lifestyle Intervention in Obese Infertile Women

**Official Title:** "Evaluation of Clinical Outcomes and Costs of a Transferable Interdisciplinary Lifestyle Intervention Pre- and Per-pregnancy in Obese Infertile Women"

**NCT ID:** [NCT01483612](https://clinicaltrials.gov/study/NCT01483612)

## Key Facts

- **Status:** COMPLETED
- **Phase:** NA
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 130
- **Lead Sponsor:** Université de Sherbrooke
- **Collaborators:** Canadian Institutes of Health Research (CIHR), Ministere de la Sante et des Services Sociaux
- **Conditions:** Female Infertility, Polycystic Ovary Syndrome, Obesity
- **Start Date:** 2012-01-20
- **Completion Date:** 2018-08
- **CT.gov Last Update:** 2023-02-02

## Brief Summary

BACKGROUND: Obesity increases the risk of polycystic ovary syndrome (PCOS), characterized by anovulatory cycles, but it is also associated with reduced fertility even in ovulatory women. Moreover, obesity increases the costs of assisted human reproduction (AHR) treatments and reduces their efficacy. In addition to fertility disorders, obesity increases significantly the risks of many complications of pregnancy, delivery and neonatal health. However, a modest loss of 5-10% of total body weight can restore ovulation and improve pregnancy rates.

OBJECTIVES: 1) To design and implement a multidisciplinary program for lifestyle management of obese women, or overweight women with PCOS, who seek fertility treatment in a secondary AHR center. 2) To evaluate lifestyle benefits of this program and assess its impact on fertility, pregnancy and neonatal outcomes, as compared to a randomly assigned control group and to similar women seen in tertiary AHR centers. 3) To assess cost per live birth, and other measures of cost-effectiveness, of this program compared to the control group and tertiary AHR centers. 4) To effectively transfer knowledge obtained through these activities to relevant stakeholders in the health care and public health sectors.

METHODS AND APPROACH: In order to design the program for lifestyle management of obesity in infertile women, we will gather a Committee composed of members of our interdisciplinary research team and relevant collaborators. Objectives 2 and 3 - In order to achieve these objectives, 128 obese women (BMI ≥ 30 kg/m²), or overweight women with PCOS (BMI ≥ 27 kg/m²), consulting at the CHUS fertility clinic will be randomized to our lifestyle program, and will suspend fertility treatments for six months, or to standard fertility treatments, which are directly initiated. The results obtained will also be compared to those of women with the same criteria who will consult in 3 tertiary AHR clinics not offering a similar lifestyle management program.

IMPACT: This project is very important as it will generate new knowledge about the implementation, impacts and costs of a new lifestyle management program in obese infertile women. Our project will obtain valuable data on implementability of such a program; on benefits with regard to lifestyle, fertility and maternal and foetal complications during pregnancy; as well as on reduction in cost per live birth and other cost-effectiveness ratio.

## Eligibility

- **Minimum age:** 18 Years
- **Maximum age:** 40 Years
- **Sex:** FEMALE
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Obese (BMI ≥ 30kg/m2) infertile women
* Overweight (BMI ≥ 27kg/m2) infertile women with polycystic ovary syndrome

Exclusion Criteria:

* Women older than 40 years old
* Women who went through bariatric surgery
* Women under IVF
* Women for whome IVF is the only recommended treatment
* Women who do not speak french
```

## Arms

- **Lifestyle counseling** (EXPERIMENTAL)
- **control** (NO_INTERVENTION)

## Interventions

- **Interdisciplinary lifestyle intervention** (BEHAVIORAL) — Individual meetings with a dietitian and a kinesiologist at 0, 3, 6 weeks and then every 6 weeks for 18 months or until delivery. A reminder phone call/email will also take place once between each meeting.

The program also includes 12 group sessions discussing subjects about nutrition, psychology and demonstration of physical activity.

## Primary Outcomes

- **Rates of live birth** _(time frame: Participants who will become pregnant: for the duration before they get pregnant and up to the end of pregnancy, an expected average of 18 months. Participants who will not become pregnant: 18 months)_

## Secondary Outcomes

- **Fertility outcomes** _(time frame: 18 months)_
- **Pregnancy outcomes** _(time frame: Participants who will become pregnant: up to the end of pregnancy, an expected average of 18 months of follow-up in the study)_
- **Neonatal outcomes** _(time frame: Participants who will become pregnant: up to the end of pregnancy, an expected average of 18 months of follow-up in the study)_
- **Clinical outcomes** _(time frame: 18 months)_
- **Cost per life birth, and other measures of cost-effectiveness** _(time frame: Participants who will become pregnant: for the duration before they get pregnant and up to the end of pregnancy, an expected average of 18 months. Participants who will not become pregnant: 18 months)_
- **Clinical outcomes in male partners** _(time frame: 18 months)_
- **Clinical outcomes of female participants** _(time frame: 18 months)_

## Locations (1)

- Centre hospitalier universitaire de Sherbrooke, Sherbrooke, Quebec, Canada

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `sponsor.collaborators` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.centre hospitalier universitaire de sherbrooke|sherbrooke|quebec|canada` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT01483612.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT01483612*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*